Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 4
F·Filter
Reset allT2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
4 sources
- 2022Reviewsuggestive
A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
Kell DB, Laubscher GJ, Pretorius E · Biochemical Journal
The synthesis paper that frames amyloid fibrin microclots as a central mechanism of long COVID/PASC symptomatology — hypothesis-grade rather than validated mechanism, and the framework that underwrites the coagulation-focused therapeutic rationale that recurs in long-COVID communities.
- 2018Cohortsuggestiven=97
Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance
Du C, Zhang C, Wu W, +7 · Pediatric Diabetes
Circulating MOTS-c was significantly lower in obese male Chinese children and adolescents than in normal-weight controls and correlated inversely with HOMA-IR — the first paediatric demonstration of the mitochondrial-derived-peptide-and-insulin-resistance association predicted by Lee 2015.
- 2013Mechanisticsuggestive
Short cell-penetrating peptides: a model of interactions with gene promoter sites
Khavinson VKh, Tarnovskaya SI, Linkova NS, +3 · Bulletin of Experimental Biology and Medicine
The Khavinson group's molecular-modeling proposal for how short peptides like Vilon (Lys-Glu) and Epitalon (Ala-Glu-Asp-Gly) could bind specific DNA promoter motifs — the in-silico mechanism that the rest of the Khavinson program leans on whenever it claims a four-residue peptide can drive selective gene expression.
- 1986Cohortsuggestiven=18
Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs
Schneider-Helmert D · European Neurology
18 chronic-insomnia patients across two age strata; middle-aged subjects (29–59) reached normal sleep values by end of one week of DSIP dosing, while elderly subjects (60–83) required the post-treatment follow-up week to achieve the same normalisation — an age-dependent response curve unique in the DSIP literature.